Slon-Usakiewicz J J, Sivaraman J, Li Y, Cygler M, Konishi Y
Biotechnology Research Institute, National Research Council of Canada, 6100 Royalmount Avenue, Montreal, Quebec H4P 2R2, Canada.
Biochemistry. 2000 Mar 7;39(9):2384-91.
Synthetic bivalent thrombin inhibitors comprise an active site blocking segment, a fibrinogen recognition exosite blocking segment, and a linker connecting these segments. Possible nonpolar interactions of the P1' and P3' residues of the linker with thrombin S1' and S3' subsites, respectively, were identified using the "Methyl Scan" method [Slon-Usakiewicz et al. (1997) Biochemistry 36, 13494-13502]. A series of inhibitors (4-tert-butylbenzenesulfonyl)-Arg-(D-pipecolic acid)-Xaa-Gly-Yaa-Gly-betaAla-Asp-Tyr-Glu-Pro-Ile-Pro-Glu-Glu-Ala- (be ta-cyclohexylalanine)-(D-Glu)-OH, in which nonpolar P1' residue Xaa or P3' residue Yaa was incorporated, were designed and improved the affinity to thrombin. Substitution of the P3' residue with D-phenylglycine or D-Phe improved the K(i) value to (9.5 +/- 0.6) x 10(-14) or 1.3 +/- 0.5 x 10(-13) M, respectively, compared to that of a reference inhibitor with Gly residues at Xaa and Yaa residues (K(i) = (2.4 +/- 0.5) x 10(-11) M). Similarly, substitution of the P1' residue with L-norleucine or L-beta-(2-thienyl)alanine lowered the K(i) values to (8.2 +/- 0.6) x 10(-14) or (5.1 +/- 0.4) x 10(-14) M, respectively. The linker Gly-Gly-Gly-betaAla of the inhibitors in the previous sentence was simplified with 12-aminododecanoic acid, resulting in further improvement of the K(i) values to (3.8 +/- 0.6) x 10(-14) or (1.7 +/- 0.4) x 10(-14) M, respectively. These K(i) values are equivalent to that of natural hirudin (2.2 x 10(-14) M), yet the size of the synthetic inhibitors (2 kD) is only one-third that of hirudin (7 kD). Two inhibitors, with L-norleucine or L-beta-(2-thienyl)alanine at the P1' residue and the improved linker of 12-aminododecanoic acid, were crystallized in complex with human alpha-thrombin. The crystal structures of these complexes were solved and refined to 2.1 A resolution. The Lys(60F) side chain of thrombin moved significantly and formed a large nonpolar S1' subsite to accommodate the bulky P1' residue.
合成二价凝血酶抑制剂包含一个活性位点阻断片段、一个纤维蛋白原识别外位点阻断片段以及连接这些片段的接头。使用“甲基扫描”方法[斯洛恩 - 乌萨基维茨等人(1997年)《生物化学》36卷,13494 - 13502页]确定了接头的P1'和P3'残基分别与凝血酶S1'和S3'亚位点可能存在的非极性相互作用。设计了一系列抑制剂(4 - 叔丁基苯磺酰基)-精氨酸 - (D - 哌啶酸)-Xaa - 甘氨酸 - Yaa - 甘氨酸 - β - 丙氨酸 - 天冬氨酸 - 酪氨酸 - 谷氨酸 - 脯氨酸 - 异亮氨酸 - 脯氨酸 - 谷氨酸 - 谷氨酸 - 丙氨酸 - (β - 环己基丙氨酸)-(D - 谷氨酸)-OH,其中引入了非极性P1'残基Xaa或P3'残基Yaa,并提高了对凝血酶的亲和力。与在Xaa和Yaa残基处为甘氨酸残基的参考抑制剂(K(i) = (2.4 ± 0.5)×10⁻¹¹ M)相比,用D - 苯甘氨酸或D - 苯丙氨酸取代P3'残基分别将K(i)值提高到(9.5 ± 0.6)×10⁻¹⁴或1.3 ± 0.5 ×10⁻¹³ M。同样,用L - 正亮氨酸或L - β - (2 - 噻吩基)丙氨酸取代P1'残基分别将K(i)值降低到(8.2 ± 0.6)×10⁻¹⁴或(5.1 ± 0.4)×10⁻¹⁴ M。前一句中抑制剂的接头甘氨酸 - 甘氨酸 - 甘氨酸 - β - 丙氨酸用12 - 氨基十二烷酸简化,使K(i)值进一步提高到分别为(3.8 ± 0.6)×10⁻¹⁴或(1.7 ± 0.4)×10⁻¹⁴ M。这些K(i)值与天然水蛭素(2.2 ×10⁻¹⁴ M)相当,但合成抑制剂的大小(2 kD)仅为水蛭素(7 kD)的三分之一。两种在P1'残基处带有L - 正亮氨酸或L - β - (2 - 噻吩基)丙氨酸以及具有改进接头12 - 氨基十二烷酸的抑制剂与人α - 凝血酶形成复合物结晶。解析了这些复合物的晶体结构并将其精修至2.1 Å分辨率。凝血酶的Lys(60F)侧链显著移动并形成一个大的非极性S1'亚位点以容纳庞大的P1'残基。